Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francisco J Esteva

Showing results (1-10 of 177) with videos related to

Pageof 18
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 21, 2015
Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of PrognosisFrancisco J Esteva
The Oncologist|May 28, 2004
Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancerFrancisco J Esteva
Oncology (Williston Park, N.Y.)|July 11, 2002
The current status of docetaxel for metastatic breast cancerFrancisco J Esteva
The Oncologist|May 2, 2008
Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?Francisco J Esteva
Breast Cancer Research : BCR|November 14, 2006
HER2 therapy: molecular mechanisms of trastuzumab resistanceRita Nahta, Francisco J Esteva
Oncology (Williston Park, N.Y.)|April 15, 2009
Optimizing outcomes in HER2-positive breast cancer: the molecular rationaleFrancisco J Esteva, Lajos Pusztai
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
HER-2-targeted therapy: lessons learned and future directionsRita Nahta, Francisco J Esteva
Seminars in Oncology|November 13, 2003
Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancerRita Nahta, Francisco J Esteva
Cancer Letters|February 7, 2006
Herceptin: mechanisms of action and resistanceRita Nahta, Francisco J Esteva
JCO Oncology Practice|March 12, 2024
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and StrategiesFrancisco J Esteva, Elena Katz
Pageof 18

Showing results (1-10 of 177) with videos related to

Sort By:
Pageof 18
Clinical Advances in Hematology & Oncology : H&O|July 21, 2015
Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of PrognosisFrancisco J Esteva
The Oncologist|May 28, 2004
Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancerFrancisco J Esteva
Oncology (Williston Park, N.Y.)|July 11, 2002
The current status of docetaxel for metastatic breast cancerFrancisco J Esteva
The Oncologist|May 2, 2008
Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?Francisco J Esteva
Breast Cancer Research : BCR|November 14, 2006
HER2 therapy: molecular mechanisms of trastuzumab resistanceRita Nahta, Francisco J Esteva
Oncology (Williston Park, N.Y.)|April 15, 2009
Optimizing outcomes in HER2-positive breast cancer: the molecular rationaleFrancisco J Esteva, Lajos Pusztai
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
HER-2-targeted therapy: lessons learned and future directionsRita Nahta, Francisco J Esteva
Seminars in Oncology|November 13, 2003
Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancerRita Nahta, Francisco J Esteva
Cancer Letters|February 7, 2006
Herceptin: mechanisms of action and resistanceRita Nahta, Francisco J Esteva
JCO Oncology Practice|March 12, 2024
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and StrategiesFrancisco J Esteva, Elena Katz
Pageof 18